Biosimilar Erosion

The loss of market share and pricing power experienced by a branded biologic drug after cheaper, highly similar follow-on biologics enter the market.

Biosimilar erosion describes the decline in sales, market share, and pricing power that a pharmaceutical company experiences when its patented biologic drug faces competition from biosimilars. Biologics are complex medicines manufactured from living cells, and biosimilars are highly similar, lower-cost versions approved once the original drug's patent protection expires. For biotechnology and pharmaceutical investors, tracking biosimilar erosion is critical for forecasting long-term revenue streams and evaluating a company's pipeline. Unlike traditional small-molecule generic drugs, which can cause immediate revenue drops of 80% or more (known as a patent cliff), biosimilar erosion is historically more gradual. This slower pace is due to complex manufacturing requirements, regulatory hurdles, physician prescribing habits, and payer formulary negotiations. Investors analyze erosion rates by monitoring the volume market share losses and average selling price (ASP) declines of the branded drug following competitor entry. A steep erosion curve can severely impact a drugmaker's operating margins and cash flow, whereas a shallow erosion curve suggests strong brand loyalty, effective defensive pricing strategies, or high switching costs for patients.

Company A's blockbuster biologic drug generates $1,000,000,000 in annual revenue at a price of $10,000 per treatment. Two biosimilar competitors enter the market, capturing 30% of the volume and forcing Company A to lower its price by 20% to $8,000 to retain the remaining 70% volume. Company A's new revenue is calculated as 70% of original volume (70,000 treatments) multiplied by the new price of $8,000, which equals $560,000,000. This represents a total biosimilar erosion of $440,000,000, or 44% of the original revenue.